NALPROPION PHARMACEUTICALS

Serial Number 88044499
Registration 5735551
700

Registration Progress

Application Filed
Jul 19, 2018
Under Examination
Jan 15, 2019
Approved for Publication
Nov 20, 2018
Published for Opposition
Nov 20, 2018
Registered
Apr 23, 2019

Attorney Assistance

Section 8 (6-Year) Declaration Due (Based on registration date 2019-04-23)
Due: Apr 23, 2025 Overdue

Basic Information

Serial Number
88044499
Registration Number
5735551
Filing Date
July 19, 2018
Registration Date
April 23, 2019
Published for Opposition
November 20, 2018
Drawing Code
3

Status Summary

Current Status
Active
Status Code
700
Status Date
Apr 23, 2019
Registration
Registered
Classes
005

Rights Holder

NALPROPION PHARMACEUTICALS LLC

16
Address
155 Franklin Road, Suite 450
Brentwood, TN 37027

Ownership History

Nalpropion Pharmaceuticals, Inc.

Original Applicant
03
Morristown, NJ

Nalpropion Pharmaceuticals, Inc.

Owner at Publication
03
Morristown, NJ

Nalpropion Pharmaceuticals, Inc.

Original Registrant
03
Morristown, NJ

NALPROPION PHARMACEUTICALS LLC

New Owner After Registration #1
16
Brentwood, TN

Legal Representation

Attorney
Andrew N. Spivak

USPTO Deadlines

Next Deadline
1384 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2019-04-23)
Due Date
April 23, 2029
Grace Period Ends
October 23, 2029

Application History

23 events
Date Code Type Description
Apr 23, 2024 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 27, 2021 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Jul 27, 2021 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 27, 2021 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jul 27, 2021 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 27, 2021 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 23, 2019 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 23, 2019 R.PR A REGISTERED-PRINCIPAL REGISTER
Mar 16, 2019 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 15, 2019 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 12, 2019 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Feb 12, 2019 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Jan 22, 2019 EISU I TEAS STATEMENT OF USE RECEIVED
Jan 22, 2019 IUAF S USE AMENDMENT FILED
Jan 15, 2019 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 20, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 20, 2018 PUBO A PUBLISHED FOR OPPOSITION
Oct 31, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 9, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 3, 2018 DOCK D ASSIGNED TO EXAMINER
Jul 25, 2018 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 24, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 23, 2018 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations for use in the treatment of obesity and inducing weight loss
First Use Anywhere: May 25, 2018
First Use in Commerce: Oct 15, 2018

Additional Information

Design Mark
The mark consists of The stylized term "NALPROPION" with a capital "N". To the left of NALPROPION is a stylized logo comprised of two curved, triangular shapes strategically placed so as to form the outline of the letter "N". Underneath the term "NALPROPION" is the stylized word "PHARMACEUTICALS" in all capital letters.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
005

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"